Ironwood Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• Ironwood Pharmaceuticals Inc IRWD.OQ reported quarterly adjusted earnings of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of five analysts for the quarter was for earnings of 4 cents per share.

• Revenue fell 9.7% to $85.24 million from a year ago; analysts expected $60.78 million.

• Ironwood Pharmaceuticals Inc's reported EPS for the quarter was 14 cents​.

• The company reported quarterly net income of $23.62 million.

• Ironwood Pharmaceuticals Inc shares had risen by 12.2% this quarter and lost 81.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 9.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Ironwood Pharmaceuticals Inc is $1.00, about 19.5% above its last closing price of $0.81

This summary was machine generated from LSEG data August 7 at 05:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)